Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| IFN-β-1a, (Avonex®)NCT00398528 | NeurognosticsPhase unknown | TERMINATED rate of enrollment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-05 |
| Glatiramer acetate, (Copaxone®)NCT00398528 | NeurognosticsPhase unknown | TERMINATED rate of enrollment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-12-05 |
| MSI-1256F (Squalamine Lactate)NCT00089830 | Genaera CorporationPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-28 |
| Squalamine LactateNCT00139282 | Genaera CorporationPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2007-11-28 |
| MSI-1256F (Squalamine Lactate)NCT00333476 | Genaera CorporationPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-28 |
| DutasterideNCT00421421 | GlaxoSmithKlinePHASE4 | TERMINATED Incomplete information | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-11-27 |
| Low dose aspirinNCT00564174 | Mount Sinai Hospital, CanadaNA | TERMINATED interim analysis found no difference in LB rate and lower than expected event rate | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-27 |
| Low molecular weight heparin and low dose aspirinNCT00564174 | Mount Sinai Hospital, CanadaNA | TERMINATED interim analysis found no difference in LB rate and lower than expected event rate | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-27 |
| Quetiapine IR (Immediate Release)NCT00457899 | AstraZenecaPHASE3 | TERMINATED Study terminated due to poor recruitment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-11-27 |
| Artemether-LumefantrineNCT00374205 | Bernhard Nocht Institute for Tropical MedicinePHASE4 | TERMINATED Interim analysis showed more LCFs in one of the treatment arms | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-11-27 |
| Artesunate plus AmodiaquineNCT00374205 | Bernhard Nocht Institute for Tropical MedicinePHASE4 | TERMINATED Interim analysis showed more LCFs in one of the treatment arms | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-11-27 |
| Rituximab, Etoposide, Methylprednisolone, Cytarabine, CisplatinNCT00367497 | Keio UniversityPHASE2 | TERMINATED The stopping rule was applied because of low response rates. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-20 |
| mycophenolate mofetil [CellCept]NCT00420472 | Hoffmann-La RochePHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2007-11-20 |
| GemfibrozilNCT00243672 | University Hospital MuensterPHASE4 | WITHDRAWN The study chair changed his employment, the realization of the study was not possible | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-19 |
| AtorvastatinNCT00243672 | University Hospital MuensterPHASE4 | WITHDRAWN The study chair changed his employment, the realization of the study was not possible | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-19 |
| BuprenorphineNCT00469053 | Grünenthal GmbHPHASE1 | TERMINATED The trail end was achived according to the definition in the trial protocol | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-16 |
| neoadjuvant chemotherapy (cisplatin, 5-fluorouracil)NCT00559351 | Ministry of Scientific Research and Information Technology, PolandPHASE3 | TERMINATED difficulty in recruitment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-16 |
| BuprenorphineNCT00469404 | Grünenthal GmbHPHASE1 | TERMINATED The trial end was achieved according to the definition in the trial protocol | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-16 |
| DexamethasoneNCT00215748 | Geriatric Oncology ConsortiumPHASE2 | TERMINATED slow accrual | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-16 |
| oxaliplatin, capecitabine, bevacizumabNCT00120172 | Geriatric Oncology ConsortiumPHASE2 | TERMINATED positive results from a larger study with same regimen was released. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-16 |
| CDOP plus rituximabNCT00120198 | Geriatric Oncology ConsortiumPHASE2 | TERMINATED slow accrual | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-16 |
| Capecitabine (Xeloda)NCT00216424 | James A. Haley Veterans Administration HospitalPHASE4 | TERMINATED lack of accrual | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-12 |
| Capecitabine (Xeloda)NCT00216437 | James A. Haley Veterans Administration HospitalPHASE1 | TERMINATED lack of accrual | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-12 |
| treprostinil sodiumNCT00458042 | United TherapeuticsPHASE4 | TERMINATED Low Enrollment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-12 |
| fosamprenavir/lopinavir/ritonavir (1400mg/533mg/100mg BID)NCT00144833 | GlaxoSmithKlinePHASE3 | TERMINATED Incomplete data | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-12 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |